Michael Sweeney
Director, Alliance Management, Business Development Operations Biodesix
Seminars
Wednesday 9th September 2026
Beyond Tissue: Liquid Biopsy Quantification of RAS Mutations and Proteomic Profiling for Patient Selection and Longitudinal Trial Monitoring
11:30 am
- Plasma cfDNA testing provides a real-time view of systemic tumor burden, helping reduce false negatives and identify patients with low-abundance or subclonal RAS variants for targeted therapy trials
- Rapid plasma cfDNA assays speed patient onboarding and trial recruitment, while longitudinal RAS monitoring enables earlier assessment of efficacy, response depth, and non-response
- Liquid biopsy proteomics can reveal non-genomic resistance mechanisms, immune microenvironment changes, and proteomic endotypes for deeper patient stratification
- Biodesix can help design and execute a customized RAS biomarker program that integrates genomic and proteomic insights
